Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 16/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 15/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 13/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 13/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 13/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 13/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218780 | 0.88 | HDAC8 (1.00) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL3218796 | 0.88 | HDAC8 (1.00) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL28881222 | 0.87 | HDAC8 (0.77) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL1249448 | 0.82 | HDAC8 (1.00) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL8131488 | 0.82 | HDAC8 (1.00) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL5664807 | 0.79 | ATM (0.72) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL17199333 | 0.74 | HDAC8 (0.74) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL29867042 | 0.71 | HDAC8 (0.55) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL12732943 | 0.71 | HDAC8 (0.55) | HDAC8HDAC10HDAC3HDAC4HDAC1 | |
| SCHEMBL14974122 | 0.71 | HDAC8 (0.74) | HDAC8HDAC10HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160378912-A1 | STRUCTURE-BASED MODELING AND TARGET-SELECTIVITY PREDICTION | EPIGENETX LLC (US) | 2016-12-29 | — | — | US | disclosed |
| WO-2015002860-A1 | STRUCTURE-BASED MODELING AND TARGET-SELECTIVITY PREDICTION | EPIGENETX, LLC (US) | 2015-01-08 | — | — | WO | disclosed |
| US-20090081318-A1 | TREATMENT OF NEUROADS USING INHIBITORS OF GLYCOGEN SYNTHASE KINASE (GSK)-3 | UNIVERSITY OF ROCHESTER | 2009-03-26 | — | — | US | disclosed |
| EP-1976976-A2 | TREATMENT OF NEUROAIDS USING INHIBITORS OF GLYCOGEN SYNTHASE KINASE (GSK)-3 | University of Rochester (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007076372-A2 | TREATMENT OF NEUROAIDS USING INHIBITORS OF GLYCOGEN SYNTHASE KINASE (GSK)-3 | UNIVERSITY OF ROCHESTER (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20060128660-A1 | FK228 analogs and methods of making and using the same | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081318-A1 | TREATMENT OF NEUROADS USING INHIBITORS OF GLYCOGEN SYNTHASE KINASE (GSK)-3 | GSK3A, GSK3B, PYGB | HDAC8 1168/4885HDAC10 1280/4885HDAC3 335/4885 |
| US-20060128660-A1 | FK228 analogs and methods of making and using the same | HDAC8, HDAC1, HDAC11 | HDAC8 1/4885HDAC10 6/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.